Skip to main content

Advertisement

Table 2 Effects of OML-based antigen immunization against P. berghei sporozoite challenge

From: Plasmodium berghei circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice

Antigen Immunization Antibody titration* Infected/total [1st+ 2ndtrials] (Number) Parasitemia* Protection(%)
  Dose Boost IgG1 IgG2a    
OML-PbCSP 3 μg 2 10666.7 ± 3304.9†† 3466.7 ± 1573.1†† 5/11 [(2/5) + (3/6)] 6.40 ± 0.55 54% (P = 0.004)
1 μg 2 4900.0 ± 2038.6†† 1200.0 ± 979.8†† 2/6 8.50 ± 2.10 66.7% (P = 0.002)
OML-PbCSP 3 μg 1 1733.3 ± 786.5†† 600.0 ± 219.1†† 5/6 6.50 ± 1.00 66.7% (P = 0.002)
1 μg 1 533.3 ± 206.6†† 266.7 ± 103.3†† 4/6 6.60 ± 1.34 33.3% (P = 0.041)
PbCSP 3 μg 1 433.3 ± 196.6 166.7 ± 51.6 11/11 [(5/5) + (6/6)] 5.83 ± 0.98 0% (N.A.)
OML-PBS   2 0 0 10/11 [(5/5) + (5/6)] 5.50 ± 1.40 5.9% (P = 0.413)
None   0 0 0 11/11 [(5/5) + (6/6)] 5.09 ± 1.04 0%
  1. *Antigen-specific IgG1 and IgG2a detected by ELISA with recombinant PbCSP l4 day after the last boost. Each value represents the mean antibody titer ± SD per mouse group.
  2. *Each value represents tie mean day of parasitemia onset ± SD per mouse group.
  3. ††Indicates a statistically significant difference between the antibody response of the OML-based antigen-immunized group to those of the corresponding group immunized with naked antigen.
  4. Mice were scored as protected when parasitemia was not observed over a 30-day pariod.
  5. Significant difference in protection rate as compared to none and as calculated by chi-test. NA.: Not applicable.
  6. Results represent pooled data of two independent experiments.